Royalty Pharma plc (NASDAQ:RPRX) Shares Purchased by Barclays PLC

Barclays PLC boosted its holdings in shares of Royalty Pharma plc (NASDAQ:RPRX) by 16.3% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 308,887 shares of the biopharmaceutical company’s stock after buying an additional 43,339 shares during the quarter. Barclays PLC’s holdings in Royalty Pharma were worth $8,737,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in RPRX. Swedbank AB increased its position in shares of Royalty Pharma by 2.0% during the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock worth $311,964,000 after acquiring an additional 213,900 shares during the period. State Street Corp grew its stake in Royalty Pharma by 0.3% during the 3rd quarter. State Street Corp now owns 9,516,262 shares of the biopharmaceutical company’s stock worth $269,215,000 after purchasing an additional 29,451 shares in the last quarter. Two Sigma Advisers LP increased its holdings in Royalty Pharma by 44.7% during the 3rd quarter. Two Sigma Advisers LP now owns 3,033,200 shares of the biopharmaceutical company’s stock worth $85,809,000 after purchasing an additional 936,900 shares during the period. Charles Schwab Investment Management Inc. raised its position in Royalty Pharma by 58.1% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 3,001,603 shares of the biopharmaceutical company’s stock valued at $84,915,000 after purchasing an additional 1,103,341 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Royalty Pharma by 6.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,972,201 shares of the biopharmaceutical company’s stock valued at $84,084,000 after buying an additional 174,874 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of RPRX opened at $25.12 on Wednesday. The company has a quick ratio of 1.54, a current ratio of 1.54 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 52-week low of $24.70 and a 52-week high of $31.66. The stock has a 50 day moving average price of $26.61 and a 200 day moving average price of $27.21. The company has a market capitalization of $14.80 billion, a price-to-earnings ratio of 13.02, a price-to-earnings-growth ratio of 4.36 and a beta of 0.46.

Royalty Pharma Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, December 10th. Investors of record on Friday, November 15th were given a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a dividend yield of 3.34%. The ex-dividend date was Friday, November 15th. Royalty Pharma’s dividend payout ratio (DPR) is 43.52%.

Analyst Upgrades and Downgrades

RPRX has been the topic of a number of recent research reports. StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a research note on Tuesday, November 5th. Citigroup dropped their price objective on shares of Royalty Pharma from $60.00 to $40.00 and set a “buy” rating on the stock in a research report on Friday, October 25th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $41.67.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.